Cipla has announced significant changes in its senior management team as part of a leadership transition. Effective 1st April 2026, Mr Achin Gupta will take charge as the Managing Director and Global Chief Executive Officer (CEO) of the company. Following this appointment, two officials reporting directly to Mr Gupta have been categorised as Senior Management Personnel (SMP).
Mr Saurabh Gambhir has been appointed as the Head of Strategy and Mergers & Acquisitions (Global) at Cipla. He will play a crucial role in shaping the company’s long-term strategic direction and driving key transformation initiatives across global markets. Before joining Cipla, Mr Gambhir held senior leadership roles at Emcure Pharmaceuticals and Intas Pharmaceuticals, where he led portfolio strategy, marketing, and business development across multiple therapeutic segments. At Cipla, he will be responsible for leading strategic planning, inorganic growth opportunities, and digital transformation programs.
Mr Satyavan Manikani has been appointed as the Chief Portfolio Head Global at Cipla. He will be instrumental in shaping the portfolio initiatives at Cipla globally. Prior to joining Cipla, Mr Manikani held leadership roles at USV Limited, Gufic Biosciences Ltd, Alkem Labs, and Ranbaxy Labs. Since joining Cipla in February 2022, he has been leading the portfolio for the Indian market, driving successful launches and aligning India’s portfolio strategy with Cipla’s global vision.
In another major development, Mr Umang Vohra has resigned as a Director of Cipla, effective 1st April 2026, following the completion of his term as the Managing Director and Global CEO on 31st March 2026. Mr Vohra expressed his gratitude to the Board and his colleagues for their support during his tenure, highlighting the pride he felt in the achievements made during his time at Cipla.
These changes reflect Cipla’s ongoing commitment to strengthening its leadership team and strategic direction as it continues to focus on innovation and growth in the pharmaceutical sector.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).